Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12006428 | 0.77 | TRPM8 (0.46) | SIGMAR1TRPM8EPHX1EPHX2 | |
| SCHEMBL988766 | 0.77 | OPRD1 (0.48) | SIGMAR1OPRD1 | |
| SCHEMBL12017850 | 0.74 | SIGMAR1 (0.64) | SIGMAR1DRD2HTR2AKMT2A | |
| SCHEMBL12006523 | 0.73 | MAPK1 (0.53) | OPRD1 | |
| SCHEMBL12410067 | 0.71 | — | — | |
| SCHEMBL13254007 | 0.69 | KMT2A (0.45) | SIGMAR1DRD2HTR2AADRA1DADRA1A | |
| SCHEMBL12494529 | 0.69 | NPSR1 (0.38) | KMT2A | |
| SCHEMBL12490701 | 0.68 | GAA (0.35) | — | |
| SCHEMBL12410062 | 0.68 | EPHX2 (0.53) | SIGMAR1ADRA1DADRA1AADRA1BEPHX2 | |
| SCHEMBL12409983 | 0.66 | HRH3 (0.38) | SIGMAR1TRPM8DRD2HTR2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | SIGMAR1 2180/4885TRPM8 243/4885DRD2 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.